Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
Every severe viral infection since the Spanish Flu has stimulated interest in passive immunotherapy, in the absence of antiviral treatment and a vaccine program [1]. The rationale for convalescent plasmatherapy is very simple: it aims at providing neutralizing antibodies raised in donors having recovered from infection, to a mate recipient developing infection, in general, with a severe presentation [2,3]. The emergence of COVID-19 has swiftly elicited interest towards convalescent plasma as complications are not exceptional and even lethal [4 –6].
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Olivier Garraud Source Type: research
More News: Clinical Trials | COVID-19 | Hematology | Immunotherapy | Science | Spain Health | Vaccines